Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials

References

• von Gruenigen VE, Huang HQ, Gil KM et al. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials. Cancer115(20), 4857–4864 (2009).
   PubMed Web of Science ®Google Scholar
• Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol.23(24), 5605–5612 (2005).
   PubMed Web of Science ®Google Scholar
• Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol.25(4), 437–443 (2007).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Constitution of the World Health Organization. Basic Documents. Geneva, Switzerland, WHO (1948).
   Google Scholar
• Eisenberg HS. A measurement of quality of survival of breast cancer patients. In: Clinical Evaluation in Breast Cancer Hayward JL, Bulbrook RD (Eds). Academic Press, London, UK (1966).
   Google Scholar
• Feinstein AR. The epidemiology of cancer therapy: II. The clinical course: data, decisions, and temporal demarcations. Arch. Intern. Med.123, 323–344 (1969).
   Google Scholar
• Retan JW. Repeated dialysis of indigent patients for chronic renal failure. Ann. Intern. Med.64(2), 284–292 (1966).
   PubMed Web of Science ®Google Scholar
• Priestman TJ, Baum M. Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet1(7965), 899–900 (1976).
   PubMed Web of Science ®Google Scholar
• Johnson JR. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat. Reports69, 1155–1157 (1985).
   PubMedGoogle Scholar
• O’Shaughnessy JA, Wittes RE, Burke G et al. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J. Clin. Oncol.9(12), 2225–2232 (1991).
   PubMed Web of Science ®Google Scholar
• Kazi R, De Cordova J, Kanagalingam J et al. Quality of life following total laryngectomy: assessment using the UW-QOL scale. ORL J. Otorhinolaryngol. Relat. Spec.69(2), 100–106 (2007).
   Google Scholar
• Morton RP, Izzard ME. Quality-of-life outcomes in head and neck cancer patients. World J. Surg.27(7), 884–889 (2003).
   PubMed Web of Science ®Google Scholar
• Murphy BA, Ridner S, Wells N, Dietrich M. Quality of life research in head and neck cancer: a review of the current state of the science. Crit. Rev. Oncol. Hematol.62(3), 251–267 (2007).
   PubMed Web of Science ®Google Scholar
• Burckhardt CS, Anderson KL. The Quality of Life Scale (QOLS): reliability, validity, and utilization. Health Qual. Life Outcomes1, 60 (2003).
   PubMedGoogle Scholar
• Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst.85(5), 365–376 (1993).
   PubMed Web of Science ®Google Scholar
• Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J. Clin. Oncol.11(3), 570–579 (1993).
   PubMed Web of Science ®Google Scholar
• Cull A, Howat S, Greimel E et al. Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur. J. Cancer37(1), 47–53 (2001).
   PubMed Web of Science ®Google Scholar
• Greimel E, Bottomley A, Cull A et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur. J. Cancer39(10), 1402–1408 (2003).
   PubMed Web of Science ®Google Scholar
• Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J. Clin. Oncol.19(6), 1809–1817 (2001).
   PubMed Web of Science ®Google Scholar
• Calhoun EA, Fishman DA, Lurain JR, Welshman EE, Bennett CL. A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecol. Oncol.93(1), 164–169 (2004).
   Google Scholar
• Sun CC, Bodurka DC, Donato ML et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol. Oncol.87(1), 118–128 (2002).
   PubMed Web of Science ®Google Scholar
• Sun CC, Bodurka DC, Weaver CB et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer13(4), 219–227 (2005).
   PubMed Web of Science ®Google Scholar
• Lakusta CM, Atkinson MJ, Robinson JW, Nation J, Taenzer PA, Campo MG. Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol. Oncol.81(3), 490–495 (2001).
   PubMed Web of Science ®Google Scholar
• Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J. Clin. Oncol.24(4), 579–586 (2006).
   PubMed Web of Science ®Google Scholar
• Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol. Oncol.108(1), 100–105 (2008).
   PubMed Web of Science ®Google Scholar
• Carmack Taylor CL, Basen-Engquist K, Shinn EH, Bodurka DC. Predictors of sexual functioning in ovarian cancer patients. J. Clin. Oncol.22(5), 881–889 (2004).
   PubMed Web of Science ®Google Scholar
• Liavaag AH, Dorum A, Bjoro T et al. A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. Gynecol. Oncol.108(2), 348–354 (2008).
   PubMed Web of Science ®Google Scholar
• Levine MN, Ganz PA. Beyond the development of quality-of-life instruments: where do we go from here? J. Clin. Oncol.20(9), 2215–2216 (2002).
   PubMed Web of Science ®Google Scholar
• Stewart. World Health Organization. World Cancer Report. IARC Press, Lyon, France (2003).
   Google Scholar
• McCartney CF, Larson DB. Quality of life in patients with gynecologic cancer. Cancer60(Suppl. 8), 2129–2136 (1987).
   PubMed Web of Science ®Google Scholar
• Ovesen L, Hannibal J, Mortensen EL. The interrelationship of weight loss, dietary intake, and quality of life in ambulatory patients with cancer of the lung, breast, and ovary. Nutr. Cancer19(2), 159–167 (1993).
   PubMed Web of Science ®Google Scholar
• Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc. Sci. Med.35(12), 1505–1509 (1992).
   PubMed Web of Science ®Google Scholar